Table 4.
Genotype frequencies and Hardy–Weinberg equilibrium analysis of the investigated gene loci in healthy (n = 87) and metritis-affected (n = 13) she-camels.
| Gene | SNPs | Number | Total | Genotyping frequency | Allelic frequency | χ2 | |||
|---|---|---|---|---|---|---|---|---|---|
| CARD9 | T132C | TT | TC | CC | P (T) | q (C) | 0.003 | ||
| Observed | 100 | 44/0.44 | 56/0.56 | 0.25 | 0.75 | ||||
| Expected | 6.25 | 37.5 | 56.25 | ||||||
| T251C | TT | TC | CC | P (T) | q (C) | 0.006 | |||
| Observed | 95/0.95 | 5/0.05 | 0.78 | 0.22 | |||||
| Expected | 60.84 | 34.32 | 4.84 | ||||||
| SIGLEC1 | A181C | AA | AC | CC | P (A) | q (C) | 0.0 | ||
| Observed | 91/0.91 | 9/0.09 | 0.70 | 0.30 | |||||
| Expected | 49 | 42 | 9 | ||||||
| VSIG4 | A164G | AA | AG | GG | P (A) | q (G) | 0.011 | ||
| Observed | 94/0.94 | 6/0.06 | 0.76 | 0.24 | |||||
| Expected | 57.76 | 36.48 | 5.76 | ||||||
| G406A | GG | GA | AA | P (G) | q (A) | 0.015 | |||
| Observed | 37/0.37 | 63/0.63 | 0.21 | 0.79 | |||||
| Expected | 4.41 | 33.18 | 62.41 | ||||||
| BTRC | T51A | TT | TA | AA | P (T) | q (A) | 0.015 | ||
| Observed | 53/0.53 | 47/0.47 | 0.31 | 0.69 | |||||
| Expected | 9.61 | 42.78 | 47.61 | ||||||
| G195A | GG | GA | AA | P (G) | q (A) | 0.0 | |||
| Observed | 91/0.91 | 9/0.09 | 0.70 | 0.30 | |||||
| Expected | 49 | 42 | 9 | ||||||
| A422G | AA | AG | GG | P (A) | q (G) | 0.001 | |||
| Observed | 48/0.48 | 52/0.52 | 0.28 | 0.72 | |||||
| Expected | 7.84 | 40.32 | 51.84 | ||||||
| SLC2A3 | T63C | TT | TC | CC | P (T) | q (C) | 6.62−E05 | ||
| Observed | 59/0.59 | 41/0.41 | 0.36 | 0.64 | |||||
| Expected | 12.96 | 46.08 | 40.96 | ||||||
| ACOD1 | G236T | GG | GT | TT | P (G) | q (T) | 0.003 | ||
| Observed | 28/0.28 | 72/0.72 | 0.15 | 0.85 | |||||
| Expected | 2.25 | 25.5 | 72.25 | ||||||
| T108C | TT | TC | CC | P (T) | q (C) | 0.009 | |||
| Observed | 93/0.93 | 7/0.07 | 0.74 | 0.26 | |||||
| Expected | 54.76 | 38.48 | 6.76 | ||||||
| CPT1A | C207T | CC | CT | TT | P (C) | q (T) | 0.002 | ||
| Observed | 65/0.65 | 35/0.35 | 0.41 | 0.59 | |||||
| Expected | 16.81 | 48.38 | 34.81 | ||||||
| G246A | GG | GA | AA | P (G) | q (A) | 0.004 | |||
| Observed | 92/0.92 | 8/0.08 | 0.72 | 0.28 | |||||
| Expected | 51.84 | 40.32 | 7.84 | ||||||
| PFKKB3 | A143C | AA | AC | CC | P (A) | q (C) | 0.001 | ||
| Observed | 89/0.89 | 11/0.11 | 0.67 | 0.33 | |||||
| Expected | 44.89 | 44.22 | 10.89 | ||||||
| ATF4 | C204A | CC | CA | AA | P (C) | q (A) | 0.004 | ||
| Observed | 92/0.92 | 8/0.08 | 0.72 | 0.28 | |||||
| Expected | 51.84 | 40.32 | 7.84 | ||||||
| GADD45B | T90C | TT | TC | CC | P (T) | q (C) | 0.0 | ||
| Observed | 91/0.91 | 9/0.09 | 0.70 | 0.30 | |||||
| Expected | 49 | 42 | 9 | ||||||
| A32G | AA | AG | GG | P (A) | q (G) | 0.001 | |||
| Observed | 71/0.71 | 29/0.29 | 0.46 | 0.54 | |||||
| Expected | 21.16 | 49.68 | 29.16 | ||||||
| SLC7A11 | G394A | GG | GA | AA | P (G) | q (A) | 0.015 | ||
| Observed | 53/0.53 | 47/0.47 | 0.31 | 0.69 | |||||
| Expected | 9.61 | 42.78 | 47.61 | ||||||
| PRDX3 | T174A | TT | TA | AA | P (T) | q (A) | 0.006 | ||
| Observed | 66/0.66 | 34/0.34 | 0.42 | 0.58 | |||||
| Expected | 17.64 | 48.72 | 33.64 | ||||||
Caspase recruitment domain family member 9 (CARD9), sialic acid binding ig like lectin 1 (SIGLEC1), v-set and immunoglobulin domain containing 4 (VSIG4); beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC); solute carrier family 2 member 3 (SLC2A3), aconitate decarboxylase 1 (ACOD1), carnitine palmitoyltransferase 1a (CPT1A), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3); activating transcription factor 4 (ATF4), growth arrest DNA damage inducible beta (GADD45B), solute carrier family 7 member 11 (SLC7A11); and peroxiredoxin 3 (PRDX3).